Amgen Introduces Second Stelara Rival In Canada
After Alvotech-Jamp Launch, Wezlana Is Billed As First Biosimilar With All Indications
Amgen has launched its Wezlana rival to Stelara in Canada, following up on Jamp and Alvotech’s recent partnered launch of the first Canadian ustekinumab biosimilar, Jamteki, with what Amgen has billed as “the first biosimilar to Stelara to be available for Canadian patients in all indications.”
